T. Rowe Price Associates Portfolio holdings
T. Rowe Price Associates, Inc., founded in 1937 by Thomas Rowe Price, Jr., is a globally recognized investment management firm headquartered in Baltimore, Maryland, known for its disciplined, research-driven approach to active investing. The company manages hundreds of billions in assets, offering a wide range of mutual funds, retirement plans, and advisory services tailored to individual investors, institutions, and financial intermediaries. Emphasizing long-term growth and a conservative investment philosophy, T. Rowe Price has built a strong reputation for its equity and fixed-income funds, often focusing on fundamental analysis to identify undervalued opportunities. Still publicly traded and independent, it remains a trusted name in the industry, balancing tradition with innovation to meet evolving client needs.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
AGN
Allergan Inc
AGN
|
+$1.3B |
| 2 |
American Airlines Group
AAL
|
+$853M |
| 3 |
Intuitive Surgical
ISRG
|
+$816M |
| 4 |
Morgan Stanley
MS
|
+$681M |
| 5 |
Wynn Resorts
WYNN
|
+$622M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Procter & Gamble
PG
|
+$1.4B |
| 2 |
eBay
EBAY
|
+$763M |
| 3 |
DISCK
Discovery, Inc. Series C Common Stock
DISCK
|
+$760M |
| 4 |
Broadcom
AVGO
|
+$757M |
| 5 |
US Bancorp
USB
|
+$686M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 16.95% |
| 2 | Consumer Discretionary | 13.63% |
| 3 | Financials | 12.8% |
| 4 | Industrials | 12.27% |
| 5 | Technology | 9.96% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1451
Myriad Genetics
MYGN
$298M
| $4.97M | ﹤0.01% |
127,600
+2,000
| +2% | +$74.4K |
|
|
ONIT
1452
Onity Group
ONIT
$327M
| $4.95M | ﹤0.01% |
8,897
-185
| -2% | -$101K |
|
1453
Expro Ltd
XPRO
$2.11B
| $4.94M | ﹤0.01% |
33,450
| – | – |
|
|
CSFL
1454
DELISTED
CenterState Bank Corporation Common Stock
CSFL
| $4.9M | ﹤0.01% |
+437,120
| New | +$4.74M |
|
1455
Unisys
UIS
$208M
| $4.78M | ﹤0.01% |
193,039
+25,100
| +15% | +$634K |
|
1456
Knowles
KN
$3.29B
| $4.75M | ﹤0.01% |
154,666
+5,700
| +4% | +$172K |
|
1457
XPO
XPO
$24.8B
| $4.74M | ﹤0.01% |
479,240
-5,022,505
| -91% | -$45.9M |
|
1458
Standex International
SXI
$3.98B
| $4.71M | ﹤0.01% |
63,200
+2,700
| +4% | +$185K |
|
1459
Marriott Vacations Worldwide
VAC
$4.21B
| $4.64M | ﹤0.01% |
79,068
+74,100
| +1,492% | +$4.15M |
|
1460
Erie Indemnity
ERIE
$13.3B
| $4.6M | ﹤0.01% |
61,100
| – | – |
|
1461
Ulta Beauty
ULTA
$22.1B
| $4.59M | ﹤0.01% |
50,167
+2,221
| +5% | +$200K |
|
1462
Cheniere Energy
LNG
$56.1B
| $4.58M | ﹤0.01% |
63,900
-4,700
| -7% | -$286K |
|
1463
Targa Resources
TRGP
$58.4B
| $4.56M | ﹤0.01% |
32,700
+23,700
| +263% | +$2.72M |
|
1464
Paylocity
PCTY
$7.88B
| $4.5M | ﹤0.01% |
+207,900
| New | +$4.1M |
|
|
ZOES
1465
DELISTED
Zoe's Kitchen, Inc.
ZOES
| $4.46M | ﹤0.01% |
+129,600
| New | +$3.76M |
|
|
SALE
1466
DELISTED
RetailMeNot, Inc. Series 1
SALE
| $4.45M | ﹤0.01% |
167,093
-118,300
| -41% | -$3.44M |
|
1467
Advance Auto Parts
AAP
$3.38B
| $4.33M | ﹤0.01% |
32,118
-462
| -1% | -$57.2K |
|
|
MXIM
1468
DELISTED
Maxim Integrated Products
MXIM
| $4.29M | ﹤0.01% |
126,921
+3,200
| +3% | +$107K |
|
1469
Children's Place
PLCE
$53.6M
| $4.27M | ﹤0.01% |
85,950
+4,000
| +5% | +$194K |
|
1470
HF Sinclair
DINO
$16.3B
| $4.25M | ﹤0.01% |
97,395
+6,303
| +7% | +$309K |
|
1471
Nektar Therapeutics
NKTR
$2.48B
| $4.25M | ﹤0.01% |
22,100
-70,793
| -76% | -$12.5M |
|
1472
Dana Inc
DAN
$3.27B
| $4.24M | ﹤0.01% |
173,500
-11,200
| -6% | -$251K |
|
|
HGG
1473
DELISTED
hhgregg Inc.
HGG
| $4.23M | ﹤0.01% |
416,050
-71,990
| -15% | -$661K |
|
|
PZN
1474
DELISTED
Pzena Investment Management, Inc. Class A
PZN
| $4.1M | ﹤0.01% |
367,290
-500
| -0.1% | -$5.33K |
|
|
TMHC
1475
DELISTED
Taylor Morrison
TMHC
| $4.05M | ﹤0.01% |
180,800
+22,600
| +14% | +$489K |
|
Similar funds
T. Rowe Price Associates's Q2 2014 Portfolio in Review
As of Q2 2014, T. Rowe Price Associates held 2,596 positions worth $463B, up 3.9% from $445B the previous quarter. Its ten largest holdings account for 12% of the portfolio.
T. Rowe Price Associates's Q2 2014 filing shows 97 new, 1,091 increased, 793 reduced and 67 closed positions. Its largest new stake was Teva Pharmaceuticals: 4,638,481 shares worth $243M. The largest sale was Procter & Gamble, an estimated $1.4B.
By sector, the portfolio is most concentrated in Healthcare at 17% of assets, up from 16% a quarter earlier, followed by Consumer Discretionary and Financials.
- T. Rowe Price Associates's largest Q2 2014 buy was Teva Pharmaceuticals: 4,638,481 shares worth $243M.
- T. Rowe Price Associates added most to Allergan Inc in Q2 2014, an estimated $1.3B increase.
- T. Rowe Price Associates's biggest Q2 2014 reduction was Procter & Gamble, cutting an estimated $1.4B.
- T. Rowe Price Associates fully exited Santander in Q2 2014, selling an estimated $134M.
- T. Rowe Price Associates's ten largest holdings make up 12% of its $463B portfolio in Q2 2014.
- T. Rowe Price Associates opened 97 new positions and closed 67 in Q2 2014.
- T. Rowe Price Associates's portfolio value rose 3.9% quarter-over-quarter to $463B.
Based on T. Rowe Price Associates's 13F filing for Q2 2014, filed 14 Aug 2014.